Skip to main content

Mucopolysaccharidosis IVA

0
Pipeline Programs
1
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioMarin Pharmaceutical
4 programs
BMN 110N/A1 trial
BMN 110PHASE_21 trial
BMN 110PHASE_21 trial
BMN 110PHASE_21 trial
Active Trials
NCT01858103Approved For Marketing
NCT01515956Completed15Est. Feb 2016
NCT01697319Terminated16Est. Oct 2014
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioMarin PharmaceuticalBMN 110
BioMarin PharmaceuticalBMN 110
BioMarin PharmaceuticalBMN 110

Clinical Trials (4)

Total enrollment: 56 patients across 4 trials

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

Start: Aug 2012Est. completion: Oct 201416 patients
Phase 2Terminated

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

Start: Apr 2012Est. completion: Nov 201425 patients
Phase 2Terminated

Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Start: Oct 2011Est. completion: Feb 201615 patients
Phase 2Completed

BMN 110 US Expanded Access Program

N/AApproved For Marketing

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.